EcoDrugPlus

Calcium Channel, Voltage-Dependent, N Type, Alpha 1b Subunit, A

Ensembl ID : ENSDLAG00005004861
Gene Symbol: CACNA1BA
1 Cross references
213 Possible Orthologues:

Calcium Channel, Voltage-Dependent, P/q Type, Alpha 1a Subunit, B

Ensembl ID : ENSDLAG00005007288
Gene Symbol: CACNA1AB
1 Cross references
196 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 1a

Ensembl ID : ENSDLAG00005025074
Gene Symbol: CACNA2D1A
1 Cross references
230 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 2a

Ensembl ID : ENSDLAG00005026435
Gene Symbol: CACNA2D2A
1 Cross references
212 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 2a

Ensembl ID : ENSDLAG00005035055
Gene Symbol: CACNA2D2A
1 Cross references
212 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 1 Subunit

Ensembl ID : ENSDLAG00005018864
Gene Symbol: CACNB1
1 Cross references
210 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 3a

Ensembl ID : ENSDLAG00005025321
Gene Symbol: CACNB3A
1 Cross references
203 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 4b

Ensembl ID : ENSDLAG00005029367
Gene Symbol: CACNG4B
1 Cross references
192 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 6a

Ensembl ID : ENSDLAG00005008871
Gene Symbol: CACNG6A
1 Cross references
181 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 7a

Ensembl ID : ENSDLAG00005008844
Gene Symbol: CACNG7A
1 Cross references
188 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 8a

Ensembl ID : ENSDLAG00005008862
Gene Symbol: CACNG8A
1 Cross references
168 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSDLAG00005021834
Gene Symbol: CACNA2D1
1 Cross references
229 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).